Search Medical Condition
Please enter condition
Please choose location

Venous Thromboembolism Clinical Trials

A listing of Venous Thromboembolism medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (56) clinical trials

To compare the efficacy of once daily injections in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy Patient Inclusion Criteria: Cancer patients with metastatic or locally advance solid tumor of the lung, pancreas, stomach, colon/rectum, bladder or ovary, planned ...

Phase

The purpose of this study is to see if rivaroxaban is useful in reducing the risk of patients developing blood clots while undergoing cancer treatment. The safety of rivaroxaban will also be studied.

Phase

This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE. This study is designed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of edoxaban against standard of care in ...

Phase

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

To assess the safety and extrapolated efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.

Phase

Evaluation of Soluble Fibrin in Thrombosis Exclusion

Rationale. Pulmonary embolism (PE) is a major public health problem. D-dimer (D-Di) assay is useful to exclude VTE (DVT and PE) but not specific, requiring irradiating and expensive imaging tests. Preliminary results suggest that the Soluble Fibrin (SF) assay has a sensitivity comparable to the D-Di one, but a higher ...

Phase N/A

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

The objective of this investigation is to assess safety and effectiveness of Xarelto under practice routine use in VTE secondary prevention after acute DVT, focusing on hemorrhagic-related AEs, recurrent venous thromboembolism (PE/DVT), all-cause mortality. This study is a company sponsored, one- arm prospective cohort study with patients to whom Rivaroxaban ...

Phase N/A

Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates

Neonates and infants aged less than 6 months who pass the screen of in- and exclusion criteria, who have been treated for at least five days with heparin and /or VKA for confirmed symptomatic or asymptomatic arterial or venous thrombosis are eligible for the study. Study treatment consists of a ...

Phase

Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients

The purpose of this study is to show feasibility (efficacy and safety) of Rivaroxaban in the treatment of VTE in cancer patients in comparison to the standard treatment with low molecular weight heparin (LMWH). Tumor patients with active cancer and newly diagnosed thromboembolic events are randomised to receive either Rivaroxaban ...

Phase

Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients

Patients holding a malignancy have a 7 to 28-fold higher risk for venous thromboembolism (VTE) than non-cancer patients(1). Since most cancer patients are currently treated in the outpatient setting, an acute episode of VTE has important implications on their care due to its effects on reduced life expectancy, high rates ...

Phase

Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs

MYELAXAT trial is multicentre, open trial which aims to evaluate the incidence of venous thromboembolic event (VTE) and the incidence of hemorrhagic complications. All patients with Myeloma treated with iMiDs and require thromboprophylaxis for 6 months, using an oral anti-Xa anticoagulant, Apixaban, in a preventive scheme, 2.5 mg x2/day

Phase